Commentary  |
Stem Cell Development & Manufacturing

Potency Assays for β-Thalassemia and Sickle Cell Disease Gene Therapy Drug Products

15 June 2022
In this Commentary article, we explore how reductions in testing complexity can improve access to hematopoietic stem cell therapies for patients with blood disorders. The provision of safe, effective therapies will help to ameliorate the worst impacts of these disorders for patients and afford them a better quality of life.

Presented by: Riccardo Biavasco, Senior Scientist at bluebird bio

Edited by: Ben Norris

Diseases such as sickle cell anaemia – caused by a mutation that induces haemoglobin precipitation and subsequent sickling of red blood cells – can be treated through stem cell gene therapy. However, reproducing and quantifying the treatment process in vitro can be tricky, time-consuming, and expensive. Potency assays provide a means of testing and quantifying the efficacy of stem cell treatments. Riccardo Biavasco, Senior Scientist at bluebird bio, explains that assays that investigate the editing efficiencies are an effective and practical approach for testing and development of stem cell gene therapies.

Potency Assay Development for Cell Therapy

When it comes to the development of new treatments for cellular diseases like sickle cell disease, patient safety and treatment efficacy is paramount. “It’s really important that we provide safe and effective therapies,” said Biavasco at Oxford Global’s Cell Therapy Analytics Symposium in March 2022. Treatment efficacy is assessed through the use of potency assays, which are run to monitor the development of cell therapies and the suitability of drug products. “In our case these therapies are based on hematopoietic stem and progenitor cells (HSPCs), which are harvested thanks to mobilisation and apheresis,” he continued. HSPCs are modified to generate corrected red blood cells upon infusion, which ultimately provide the clinical benefits to β-thalassemia and sickle cell disease patients.

“Once enriched with the CD34 marker, the cells are transduced with lentiviral vectors that integrate the therapeutic transgene,” Biavasco explained. Modified HSPCs are subsequently cryopreserved, then tested for safety and efficacy, after which they can be infused into their source patients. bluebird bio runs a suite of potency assays to demonstrate that the integrated transgene is able to stably express the therapeutic protein and correct the disease phenotype. One of the key determinants is the vector copy number (VCN), which ensures that an appropriate amount of the lentiviral vector (LVV) is integrated in the drug product.

In Vitro Cell Therapy Analysis

Biavasco then gave an overview of the physiologic process that bluebird bio’s assays are modelling. “It all starts with the stem cells, the same ones that we want to correct in our patients,” he said. “These cells go through different steps of maturation, and they become more and more committed to the erythroid lineage until they start to really express the haemoglobin.” On reaching a haemoglobin threshold, the nucleus starts to condense, and once fully condensed is ejected from the cells.

“It’s one of the last steps in the maturation of red blood cells” said Biavasco. “So, this is what happens in vivo. We need to reproduce this in vitro, which is quite a challenge.” Fortunately, bluebird bio is up to the task and has developed a cell culture system that enables erythroid differentiation in vitro. In β-thalassemia, cell growth and maturation are constrained by the absence of β-globin. “Erythroid cells mature until they reach the point they really need haemoglobin, and there they get stuck,” Biavasco continued. The solution involves the administration of autologous CD34 hematopoietic stem cells to provide a continuous and durable source of corrected red blood cells.

Potency assays; developing hematopoietic stem cells that mature into healthy red blood cells with the presence of HbAT87Q.
Figure. 1 – Developing hematopoietic stem cells that mature into healthy red blood cells with the presence of HbAT87Q.

These HSPCs are transduced with an LVV-encoding human β-globin with an amino acid substitution (T87Q). This substitution confers anti-sickling properties to the haemoglobin derived from gene therapy – HbAT87Q – which can subsequently be quantified in the erythroid progeny of transduced HSPCs. Biavasco added that two distinct potency assays, tailored to each disease, are required to measure the impact of HBAT87Q expression. “What we want to see in our drug products is that once we add our therapeutic HBAT87Q, we can restore the physiologic maturation of red blood cells in vitro.” In β-thalassemia, HbAT87Q corrects the maturation arrest, while also correcting for sickle cell morphology in sickle cell disease.

Potency Assays: Vector Copy Number is Top

Product potency is a key aspect of the overall process, as it provides a good indication as to whether the treatment is effective. Here, potency can be measured as a relative increase in the percent of mature erythroid cells or a relative decrease in the percent of sickled cells. Biavasco cautioned that it was not possible to show potency without accounting for the subject-specific background. “The absolute amount of in vitro mature erythroid cells or sickle cells deriving from the transduced cell is meaningless,” he said. “But as long as maturation percent increase or sickling percent decrease passes a specific threshold, the product is considered potent.”

Mechanism of action (MOA)-specific potency assays test for potential risks where a drug product contains LVV integrations that do not express the desired therapeutic protein or are are sequestered in a disproportionately small subset of cells. Testing for these risks necessarily increases the assay complexity, so there is a trade-off in information gained, time, and efficiency. “These assays can be measured in a semi-quantitative way,” said Biavasco. “But they come with a cost, and the cost is assay complexity.”

Part of the issue is the high impact of patient-to-patient variability, particularly with regard to the starting material. However, VCN is a valuable indicator to test for because it is simple, can be applied to many different diseases, and has a very quantifiable readout. “Cell editing measures are much stronger predictors of clinical efficacy compared to the MOA-specific readouts,” said Biavasco.

Future Indications and Applications for Potency Assays

One of Biavasco’s main conclusions from the presentation was that the VCN is a strong indicator of treatment efficacy to monitor for in potency assays. “Vector copy number and percent transduced cells nicely trend together,” he said, “and one can predict the other.” Drug products with VCNs above specification reliably achieve high and stable HBAT87Q expression. VCN is predictive of clinical efficacy, which Biavasco described as a “challenging accomplishment” for cell and gene therapy drug products.

“Looking to the future, we would like gene therapy to be as accessible as possible.”

“The VCN, and transduction measures in general, is our best predictor of clinical efficacy,” Biavasco said. Despite expressing the same therapeutic protein, β-thalassemia and sickle cell disease require different MOA-specific potency assays. “In the end, the VCN correlates with more or less all the different potency assays,” added Biavasco. He rounded off by concluding that thoughtful reductions in testing complexity and cost can improve access to hematopoietic stem cell therapies for patients worldwide, while maintaining appropriate monitoring of drug products safety and quality. “Looking to the future, we would like gene therapy to be as accessible as possible to all patients in the world.”


Visit our Cell portal to read more articles investigating the applications of stem cell therapies and potency assays. If you’d like to register your interest in our upcoming Cell UK: In-Person event on 07 – 08 November 2022, click here.

Speaker Biographies

Riccardo leads the hematopoietic stem cell (HSC) analytics group within Analytical Development at bluebird bio. He is responsible for development of drug product characterization assays, regulatory submission documents and interactions with regulatory agencies. Within HSC analytics, he compiles data generated by the group to advance product knowledge and foster comparability and correlative studies. The HSC analytics group supports clinical investigations and the execution of developed drug product characterization assays for Quality Control and Process Development.

Share this article

Share on facebook
Share on twitter
Share on linkedin

Sign up for our monthly Cell Newsletter

You may also be interested in...

Insight Article
Regenerative medicine is a highly promising branch of pharmacology. With the growing demand for stem cell therapies, the need for streamlined manufacturing is more critical than ever. We sat down with senior representatives from Procella Therapeutics, the University of Reading, and Newcastle University to learn more about the future of stem cell production.
29 January 2022
Commentary
Dr Darius Widera shows us three case studies on 3D stem cell cultivation using fibrin, nanofibrillar cellulose, and hybrid scaffolds
28 January 2022

Continue browsing

Share this article

Share on facebook
Share on twitter
Share on linkedin

Join our Cell mailing list

We produce cutting edge congresses and summits for the Life Sciences Industry, bringing together industry leaders and solution providers at a senior level, creating the opportunity to partner, network and knowledge share.

Contact Us:

Copyright Oxford Global Marketing Limited. All rights reserved.

Member Community Login

Stay up to date

Sign up for our monthly Editorial Newsletter to keep up with all things Cell